Table 4.
Inflammatory markers, lipids and disease activity by treatment group
| Mean change in Omega-3 group (SD) (N = 42) |
Mean change in placebo group (SD) (N = 43) |
p value* | Adjusted p value** | |
|---|---|---|---|---|
| sICAM-1, ng/mL | −1.61 (40.27) | −5.56 (48.74) | 0.2456 | 0.2429 |
| sVCAM-1, ng/mL | −17.52 (101.65) | 26.57 (135.98) | 0.0918 | 0.1218 |
| IL-6, pg/mL | −1.95 (11.16) | −27.60 (186.37) | 0.2447 | 0.5847 |
| Cholesterol, mg/dL | 3.36 (27.24) | −6.48 (22.95) | 0.0228 | 0.0099 |
| Triglycerides, mg/dL | −43.45 (71.71) | −29.48 (61.81) | 0.7041 | 0.8441 |
| HDL, mg/dL | 2.55 (8.49) | −2.21 (11.87) | 0.0929 | 0.1934 |
| LDL, mg/dL | 3.11 (21.99) | −1.87 (18.29) | 0.0266 | 0.0093 |
| LDL/HDL ratio | −0.003 (0.39) | 0.004 (0.40) | 0.3756 | 0.2132 |
| PGAa | 0.07 (0.54) | 0.21 (0.44) | 0.2914 | 0.3300 |
| SLEDAIb | −0.17 (1.87) | 0.51 (2.18) | 0.1122 | 0.1801 |
*
Based on ANCOVA model using baseline values as a covariate
**
Based on ANCOVA modeling using baseline values, use of any anti-hypertensives, diabetes, average daily use of prednisone during the follow-up period, weight, urine protein-to-creatinine ratio and systolic BP as covariates
a
PGA—physician global assessment on a 0–3 visual analog scale
b
SLEDAI—SELENA revision of Systemic Lupus Erythematosus Disease Activity Index